As per DelveInsight, the Global Cardiac Ablation Devices Market was valued at USD 2.25 billion in 2021 and growing at a CAGR of 12.77% during the forecast period (2022 to 2027); it is expected to reach USD 4.63 billion by 2027. The Global Cardiac Ablation Devices Market is anticipated to grow owing to the rise in the prevalence of cardiovascular diseases, technological advancements, increasing geriatric population, and greater penetration and acceptance of Cardiac Ablation Devices in emerging countries. Some of the key companies in the Global Cardiac Ablation Devices Market include Abbott Laboratories, Boston Scientific Corporation, Avanos Medical, Inc., Auris Health, Inc., Olympus, CONMED Corporation, ERBE ELEKTROMEDIZIN GMBH, AngioDynamics, Medtronic Inc., AtriCure, Inc., Biosense Webster, Inc., Teleflex Incorporated, St. Jude Medical Inc., Lepu Medical Technology(Beijing)Co., Ltd., MicroPort Scientific Corporation, and others.
DelveInsight’s “Cardiac Ablation Devices Market Insight, Competitive Landscape and Market Forecast – 2027” research report provides the current and forecasted Cardiac Ablation Devices market size, share, and trends analysis for the next five years. Moreover, it highlights the ongoing innovations in the segment, major market drivers & barriers, key competitors, and emerging devices in the domain.
Cardiac Ablation Devices Market: Overview
Cardiac Ablation is a surgical technique that can correct cardiac arrhythmias by scarring tiny heart regions. Cardiac arrhythmias arise when there is a deficiency of the electrical impulses that regulate the heartbeats. As a consequence, heartbeats are irregular and can lead to stroke or heart failure if left untreated, and are one of the main causes of death. The global demand for Cardiac Ablation devices is projected to record significant growth due to a rise in the geriatric population and an increase in the cardiovascular disease population base.
DelveInsight’s “Cardiac Ablation Devices Market” provides a key assessment of the market by technology (radiofrequency ablation, electrical ablation, cryoablation, ultrasound ablation, microwave ablation), Cardiac Ablation devices by product (radiofrequency ablators [temperature-controlled radiofrequency ablators, fluid-cooled radiofrequency ablators, robotic catheter manipulation systems], electrical ablators [argon plasma/beam coagulators, irreversible electroporation systems], cryoablation devices [tissue contact probes, others], ultrasound ablators [high-intensity focused ultrasound ablators, ultrasound ablation systems, others], microwave ablators [microwave thermotherapy devices]), by application (cardiac rhythm management, open surgery, others), Cardiac Ablation devices market by end-user (hospitals, cardiac centers, ambulatory surgical centers), and Cardiac Ablation devices market by geography (North America, Europe, Asia-pacific, and rest of the world).
As per the assessment, Radiofrequency Ablators are expected to hold the largest share in the Cardiac Ablation Devices market product segment. Radiofrequency Ablator is one of the fastest-growing segments in the market owing to several advantages associated with these devices. Radiofrequency Ablator is minimally invasive, enables excellent local tumor control, has promising long-term survival, and is a multimodal approach.
The Cardiac Ablation Devices Market is anticipated to observe immense growth in the coming years owing to the rise in the prevalence of cardiovascular diseases like atrial fibrillation, cardiac arrhythmia, and stroke. Atrial fibrillation is a major risk factor for ischemic stroke and provokes an important economic burden and significant morbidity and mortality. It is observed that the risk for atrial fibrillation increases with age. High blood pressure, the risk which also increases with advancing age, accounts for about 1 in 5 cases of atrial fibrillation.
Similarly, various factors are directly linked with cardiac arrhythmia, leading to a rise in the number of cases globally. The major risk factor for cardiac arrhythmia includes pre-existing medical conditions such as diabetes, hypertension, hyperthyroidism, mental stress, heart conditions, old age, and lifestyle-associated factors such as smoking, alcohol abuse, drug abuse, excessive caffeine consumption, and others. Furthermore, some dietary supplements, herbal treatments, and specific medications may also lead to cardiac arrhythmia. Overall, cardiovascular disease rises directly stimulate the demand for Cardiac Ablation Devices. The rising number of elderly patients will also transform healthcare delivery and create a greater demand for Cardiac Ablation Devices. Moreover, major MedTech companies are actively investing and increasing their manufacturing capacity for essential medical device products, including Cardiac Ablation Devices, to cater to the growing demand and grab the market share.
Despite several favorable factors, some of the key aspects, such as product recalls and unfavorable regulatory scenarios, are expected to hamper the Global Cardiac Ablation Devices market growth.
Interested to know more about the ongoing developments in the market? Visit to get an in-depth insight @ Cardiac Ablation Devices Types and Emerging Products
As per the estimate, North America is anticipated to dominate the overall Cardiac Ablation Devices market in the coming years. Some of the key factors, such as the growing demand for advanced and minimally-invasive technologies and the increased cardiovascular disease in the region, are expected to drive the Cardiac Ablation Devices market. It is observed that heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. As per the estimate, in the United States, about 670,000 new cases of heart failure are diagnosed each year. Moreover, in 2020, about 6.2 million adults had heart failure. In addition, about 655,000 Americans die from heart disease yearly; that’s 1 in every 4 deaths. The leading cases are stimulating the demand for better and improved devices. Similarly, the rising geriatric population, the growing awareness, and the rise in the number of research and development activities to improve current technologies are also leading to the growth of Cardiac Ablation Devices in the region.
As per the assessment, Europe and Asia-Pacific region also have high growth potential for the Global Cardiac Ablation Devices market owing to the rising burden of cardiovascular disease (CVD) and chronic diseases;
Interested in knowing how the market will grow by 2027? Click to get a snapshot @ Cardiac Ablation Devices Market Trends and Developments
Cardiac Ablation Devices Market – Key Developments and Breakthroughs
Over the years, the Cardiac Ablation Devices market has evolved significantly, owing to the active participation of the global MedTech companies and technological advancements in the domain. Similarly, several clinical, commercial, and regulatory developments have also been registered in the domain. Some of the major advancements in the Cardiac Ablation Devices market in recent years include –
- In August 2021, the Stereotaxis and Shanghai Microport EP Medtech Co., Ltd. announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China. The agreement combines MicroPort EP’s commercial and product leadership in China’s electrophysiology market with Stereotaxis’ advanced Robotic Magnetic Navigation technology. MicroPort EP will also pursue regulatory approvals for Stereotaxis’ latest innovations, including the Genesis RMN® system and proprietary magnetic ablation catheter.
- In August 2021, Acutus Medical announced that its suite of new algorithms for the mapping and ablation of complex atrial arrhythmias received FDA clearance and CE mark approval.
- In June 2021, The FDA granted a new indication to a cryoballoon ablation catheter that allows it to be used as a first-line treatment for atrial fibrillation before antiarrhythmic drugs. Until the new indication for the catheter (Arctic Front Advance, Medtronic), catheter ablation was approved only for use in patients with atrial fibrillation who had failed antiarrhythmic drug therapy.
Learn more about the ongoing development in the market @ Cardiac Ablation Devices Market – Clinical and Commercial Development Activities
Globally, some of the leading MedTech giants working in the Cardiac Ablation Devices market include Abbott Laboratories, Boston Scientific Corporation, Avanos Medical, Auris Health, Olympus, CONMED Corporation, ERBE ELEKTROMEDIZIN GMBH, AngioDynamics, Medtronic Inc., AtriCure, Inc., Biosense Webster, Teleflex Incorporated, St. Jude Medical, Lepu Medical Technology (Beijing), MicroPort Scientific Corporation, and others. Owing to the rising demand and favorable growth opportunities for revenue generation, several new players are anticipated to enter the market, thereby leading to high competitiveness in the domain.
Learn how new players’ entries will transform the market dynamics in the coming years @ Cardiac Ablation Devices Competitive Landscape
Scope of the Cardiac Ablation Devices Market Report:
- Study Period – 2019-2027
- Geography Covered – North America, Europe, Asia-Pacific, and Rest of the World
- Cardiac Ablation Devices Market Assessment –
- By Technology – Radiofrequency (RF) Ablation, Electrical Ablation, Cryoablation, Ultrasound Ablation, Microwave Ablation), Cardiac Ablation Devices
- By Product – Radiofrequency (RF) Ablators (Temperature-Controlled Radiofrequency Ablators, Fluid-Cooled Radiofrequency Ablators, Robotic Catheter Manipulation Systems), Electrical Ablators (Argon Plasma/Beam Coagulators, Irreversible Electroporation Systems), Cryoablation Devices (Tissue Contact Probes, Others), Ultrasound Ablators (High-Intensity Focused Ultrasound Ablators, Ultrasound Ablation Systems, Others), Microwave Ablators (Microwave Thermotherapy Devices)
- By Application – Cardiac Rhythm Management, Open Surgery, Others
- By End User – Hospitals, Cardiac Centers, Ambulatory Surgical Centers
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s Views
Table of Content
|3||Regulatory and Patent Analysis|
|4||Cardiac Ablation Devices Market Key Factors Analysis|
|5||Cardiac Ablation Devices Porter’s Five Forces Analysis|
|6||COVID-19 Impact Analysis on the Cardiac Ablation Devices Market|
|7||Cardiac Ablation Devices Market Layout|
|8||Cardiac Ablation Devices Global Company Share Analysis – Key 3–5 Companies|
|9||Cardiac Ablation Devices Product Profiles and Key Companies|
Reach out to us to get a more detailed overview of the market @ Cardiac Ablation Devices Market Insights, and Competitive Landscape
Other Trending Report by DelveInsight
The global cardiac arrhythmia monitoring devices market will grow at a CAGR of 6.33% during the forecast period from 2022 to 2027. The Cardiac Arrhythmia Monitoring Devices market is expected to grow owing to the rising prevalence of cardiovascular diseases, increasing expenditure on cardiac health globally, growing adoption of mobile and telemetry cardiac monitors, rising prevalence of cardiac arrhythmias, and rising technological advancements.
“Cardiac Arrythmia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cardiac Arrythmia, historical and forecasted epidemiology as well as the Cardiac Arrythmia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
DelveInsight’s “Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
“Acute ischemic stroke (AIS) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acute ischemic stroke (AIS), historical and forecasted epidemiology as well as the Acute ischemic stroke (AIS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
“Atrial Fibrillation – Pipeline Insight, 2023” report provides comprehensive insights about 5+ companies and 5+ drugs in the Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage drugs by product type, stage, route of administration, and molecule type.
“Ischemic Stroke Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 50+ drugs in the Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage drugs by product type, stage, route of administration, and molecule type.
“Acute Ischemic Stroke Pipeline Insight, 2023” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage drugs by product type, stage, route of administration, and molecule type.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Leverage the potential of consulting services to overcome the competition in the highly evolving and dynamic healthcare market with Healthcare Partner Identification Solutions and Healthcare Portfolio Management Services.
Manager (Marketing & Branding)